Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • Day One Biopharmaceuticals' Non Operating Income fell 3058.75% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 8408.85%. This contributed to the annual value of $128.9 million for FY2024, which is 65184.0% up from last year.
  • Day One Biopharmaceuticals' Non Operating Income amounted to $4.5 million in Q3 2025, which was down 3058.75% from $4.7 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Non Operating Income peaked at $112.0 million during Q2 2024, and registered a low of $3.4 million during Q2 2023.
  • For the 3-year period, Day One Biopharmaceuticals' Non Operating Income averaged around $15.7 million, with its median value being $5.0 million (2023).
  • Per our database at Business Quant, Day One Biopharmaceuticals' Non Operating Income skyrocketed by 320144.5% in 2024 and then crashed by 9584.46% in 2025.
  • Day One Biopharmaceuticals' Non Operating Income (Quarter) stood at $5.0 million in 2023, then increased by 21.69% to $6.1 million in 2024, then decreased by 25.72% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4.7 million for Q2 2025, and $5.1 million during Q1 2025.